🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Liège
Clinical trial register · Belgium

Clinical Trials in Liège, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Belgium and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3062 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
3062
Studies in scope
all four open statuses
1741
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Leuven 1265 Brussels 1116 Ghent 1043 Liège 564 Edegem 437
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca37 AbbVie30 University of Liege29 Janssen Research & Development, LLC26 Centre Hospitalier Universitaire de Liege19
Site location
Leuven1265 Brussels1116 Ghent1043 Liège564 Edegem437
All 201 locations
Target enrolment
to

Trials with a site in Liège

565 of 3062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Belgium
Start
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
Leuven, Liège
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
Liège
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Liège
2024-09-17
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
Brussels, Liège, Namur
2024-09-11
By invitation
Transmural Care for Chronically Ill Children: Scientific Guidance and Evaluation of Pilot Projects
NCT06679595Chronic Diseases in Children, Chronic Diseases in Adolescence, Health Personnel, Parents
University Hospital, Ghent
Observational
1,000
Brussels, Charleroi, Edegem, Ghent, Jette, La Louvière, Leuven, Liège
2024-09-10
Recruiting
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
NCT06652633Hematological Malignancies
Lakefront Biotherapeutics NV
Phase 3
546
Edegem, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2024-09-09
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsTrosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Bonheiden, Anderlecht, Brussels, Liège, Yvoir, Leuven, Kortrijk, Ostend
2024-09-04
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
DrugsS095029·Keytruda·Pembrolizumab
Servier Bio-Innovation LLC
Phase 1/2
48
Leuven, Liège
2024-08-31
Active, closed
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,000
Bruges, Genk, Jette, Liège
2024-08-30
Recruiting
The TRICURE EU Pivotal Study
NCT06581471Tricuspid Valve Regurgitation, Heart Valve Disease, Cardiovascular Diseases
TRiCares
Not applicable
80
Aalst, Antwerp, Brussels, Liège, Roeselare
2024-08-29
Recruiting
Testing and Evaluating a Psychoeducation Tool and Guidelines for Victims of Violence in Belgian Hospitals.
NCT06780540Enhance Care to Victims of Violence
University Hospital, Ghent
Not applicable
600
Antwerp, Brussels, Charleroi, Ghent, Liège, Roeselare, Saint-Servais
2024-08-24
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Anderlecht, Edegem, Ghent, Leuven, Liège, Roeselare
2024-08-12
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Edegem, Brussels, Leuven, Liège, Namur
2024-08-08
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
108
Edegem, Aalst, Ghent, Leuven, Liège
2024-07-29
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
DrugTelitacicept
Vor Biopharma
Phase 3
180
Leuven, Liège
2024-07-17
Recruiting
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
NCT06047262Diabetes Mellitus, Type 2
DrugDapansutrile
Marc Donath
Phase 2
300
Liège
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Brussels, Ghent, Liège
2024-07-09
By invitation
All-ceramic Restorations: a Retrospective and Prospective Study
NCT07110220Tooth Disorder, Missing Tooth/Teeth
Mainjot Amélie
Observational
200
Liège
2024-07-02
Not yet open
Understanding Lung Cancer Related Risk Factors and Their Impact
NCT06473870Lung Cancer Screening
Biobizkaia Health Research Institute
Observational
6,160
Liège
2024-07
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6
Boehringer Ingelheim
Phase 1/2
768
Brussels, Edegem, Leuven, Libramont-Chevigny, Liège, Namur
2024-06-28
Recruiting
Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease
NCT06502873Inflammatory Bowel Disease (IBD)
Artialis
Not applicable
120
Liège
2024-06-28
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
DrugSecukinumab
Novartis Pharmaceuticals
Phase 3
162
Liège
2024-06-28
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Anderlecht, Brussels, Jette, Charleroi, Ghent, Leuven, Liège
2024-06-27
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Leuven, Liège
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Brussels, Ghent, Leuven, Liège, Namur
2024-06-25
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
DrugTralokinumab
LEO Pharma
Phase 3
195
Brussels, Ghent, Leuven, Liège
2024-06-10
Active, closed
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122Follicular Lymphoma
DrugsVincrystine·Mosunetuzumab·Obinutuzumab·Doxorubicin
The Lymphoma Academic Research Organisation
Phase 3
790
Bruges, Brussels, Charleroi, Ghent, La Louvière, Liège, Yvoir
2024-06-07
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Antwerp, Leuven, Liège, Roeselare, Yvoir
2024-06-03
Active, closed
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification
DrugsELVN-002·Eribulin·Leucovorin·Adrucil
Enliven Therapeutics
Phase 1
275
Brussels, Liège, Wilrijk
2024-05-30
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan
Daiichi Sankyo
Phase 3
540
Brussels, Edegem, Hasselt, Liège, Roeselare, Yvoir
2024-05-21
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Antwerp, Brussels, Ghent, Leuven, Liège, Yvoir
2024-05-06
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685Ischemic Stroke, Atrial Fibrillation
DrugDOAC
Insel Gruppe AG, University Hospital Bern
Not applicable
482
Bruges, Brussels, Charleroi, Leuven, Liège
2024-05-01
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Aalst, Bonheiden, Charleroi, Ghent, La Louvière, Leper, Leuven, Liège
2024-04-27
Recruiting
Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation
NCT06383377Bone Regeneration, Safety Issues
Wishbone SA
Not applicable
96
Louvain-la-Neuve, Aubel, Chaudfontaine, Liège, Namur
2024-04-26
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
Brussels, Erpent, Ghent, Leuven, Liège
2024-04-26
Active, closed
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935Crohn's Disease
DrugsTremfya·Guselkumab
Janssen-Cilag Ltd.
Phase 3
120
Ghent, Liège, Sint-Niklaas
2024-04-17
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bruges, Brussels, Ghent, Leuven, Liège, Overpelt, Woluwe-Saint-Lambert
2024-04-16
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab Deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Anderlecht, Bruges, Hasselt, La Louvière, Liège
2024-04-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Brussels, Charleroi, Ghent, Leuven, Liège
2024-04-10
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438Non-Small Cell Lung Cancer
DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
840
Edegem, Brussels, La Louvière, Liège, Ghent, Namur
2024-04-10
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
Kortrijk, Liège
2024-04-04
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Leuven, Liège
2024-04-03
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Anderlecht, Brasschaat, Liège, Roeselare
2024-04-02
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Aalst, Bonheiden, Brussels, Ghent, Ieper, Kortrijk, Leuven, Liège
2024-03-29
Recruiting
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
NCT07136844Neuromuscular Diseases, Obesity (Disorder), Myotonic Dystrophy 1, Myasthenic Syndrome
Centre Hospitalier Universitaire de Liege
Not applicable
300
Liège
2024-03-29
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
DrugsLutikizumab·Humira·Adalimumab
AbbVie
Phase 2
156
Anderlecht, Ghent, Sint-Niklaas, Leuven, Liège
2024-03-23
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Brussels, Charleroi, Edegem, Ghent, Liège, Yvoir
2024-03-21
Active, closed
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386Asthma
DrugMepolizumab
GlaxoSmithKline
Phase 4
336
Kortrijk, Liège
2024-03-20
Recruiting
A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms
NCT06104631Irritable Bowel Syndrome-like Symptoms, Crohn Disease Remission
Biokuris s.a.
Not applicable
50
Liège
2024-03-12
Recruiting
The NEU-STIM Trial
NCT05942924Infant, Premature, Diseases, Birth, Preterm
Leiden University Medical Center
Not applicable
3,280
Liège
2024-03-11
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
DrugZasocitinib
Takeda
Phase 2
268
Brussels, Leuven, Liège
2024-03-05
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
DrugsSigvotatug vedotin·Docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Brasschaat, Edegem, Ghent, Hasselt, Liège
2024-02-21
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
Brasschaat, Edegem, Brussels, Liège, Ghent, Leuven, Roeselare
2024-02-05
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Brussels, Ghent, Liège
2024-01-30
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsTemodal·Lomustine·Temozolomide·Carboplatin
CarThera
Phase 3
560
Brussels, Leuven, Liège
2024-01-29
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Woluwe, Leuven, Bruges, Ghent, Liège, Roeselare
2024-01-23
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel
DualityBio Inc.
Phase 3
541
Brussels, Ghent, Jette, Leuven, Liège, Roeselare
2024-01-18
Recruiting
Psychoneurological Symptom Cluster in Oncology
NCT05867966Cancer, Breast Cancer, Digestive Cancer
University of Liege
Not applicable
500
Liège
2024-01-16
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Liège, Namur, Sint-Niklaas
2024-01-11
Recruiting
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
NCT06836557Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
DrugTradipitant
Vanda Pharmaceuticals
Phase 3
100
Leuven, Liège
2024-01-09
Recruiting
Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases
NCT06360913Inborn Errors of Metabolism, Rare Diseases
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Not applicable
2,286
Brussels, Charleroi, Liège
2024-01-03
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Anderlecht, Antwerp, Brussels, Leuven, Liège, Wilrijk
2023-12-30
Recruiting
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
NCT06279741Bronchopulmonary Dysplasia
EXO Biologics S.A.
Phase 1/2
265
Brussels, Charleroi, Liège
2023-12-28
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Brussels, Bonheiden, Edegem, Leuven, Liège, Stene
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Brussels, Charleroi, Ghent, Liège
2023-12-19
Recruiting
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
NCT06282588Prostate Cancer
DrugsDecapeptyl·Elacestrant·Darolutamide
Cancer Research Antwerp
Phase 2/3
493
Wilrijk, Aalst, Bruges, Brussels, Ghent, Kortrijk, Liège, Roeselare
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Bruges, Brussels, Edegem, Leuven, Liège
2023-12-13
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Brussels, Ghent, Leuven, Liège, Namur, Wilrijk
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Edegem, Brussels, Jette, Liège, Leuven
2023-12-11
Recruiting
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
NCT05872204Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
DrugsAbemaciclib·Letrozole
Universitaire Ziekenhuizen KU Leuven
Phase 2
100
Liège, Ghent, Leuven
2023-11-30
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Bonheiden, Aalst, La Louvière, Ronse, Bruges, Roeselare, Brussels, Liège
2023-11-30
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
DrugBNT314
BioNTech SE
Phase 1
41
Antwerp, Liège
2023-11-30
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
467
Brussel/ Brussels/bruxelles, Ghent, Liège, Woluwe-Saint-Lambert
2023-11-29
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
Liège
2023-11-29
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Brussels, Edegem, Ghent, Jette, Leuven, Liège, Woluwe-Saint-Lambert
2023-11-29
By invitation
EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES
NCT07233512Alzheimers Disease, Periodontitis
Centre Hospitalier Universitaire de Liege
Not applicable
26
Liège
2023-11-17
Recruiting
Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
NCT05665608Sudden Cardiac Death, Myocardial Infarction
Charite University, Berlin, Germany
Not applicable
3,595
Aalst, Bruges, Liège, Yvoir
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Auderghem, Ghent, Leuven, Liège, Mechelen
2023-11-16
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
DrugsOdronextamab·Vincristine·Doxorubicin·Rituximab
Regeneron Pharmaceuticals
Phase 3
733
Ghent, Sint-Niklaas, Bruges, Kortrijk, Brussels, Liège
2023-11-14
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Brussels, Ghent, Leuven, Liège
2023-11-08
By invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
NCT06066580Becker Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
260
Ghent, Leuven, Liége
2023-11-02
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
Aalst, Antwerp, Brussels, Ghent, Leuven, Liège
2023-10-30
Recruiting
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
Drugs177Lu-edotreotide·Everolimus
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
170
Edegem, Brussels, Liège
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Yvoir, Leuven, Brussels, Kortrijk, Liège
2023-10-25
Active, closed
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
NCT05952206Coronary Artery Disease
Drug12-month DAPT
iVascular S.L.U.
Phase 3
2,312
Bonheiden, Charleroi, Genk, Liège, Mons, Roeselare, Turnhout
2023-10-13
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Anderlecht, Brussels, Jette, Ghent, Torhout, Liège
2023-10-11
Recruiting
Incidence of Episodes of (Dis)Connected Consciousness Among Emergency Patients Admitted in the Resuscitation Room
NCT06362525Critical Illness, Near-Death Experience, Consciousness, Loss of, Quality of Life
University of Liege
Observational
100
Liège
2023-10-09
Recruiting
TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)
NCT05903066Crohn Disease
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Observational
210
Liège
2023-09-28
Recruiting
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
NCT05805033Healthy Subjects
Centre Hospitalier Universitaire de Liege
Not applicable
40
Liège
2023-09-22
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Anderlecht, Brussels, Kortrijk, Liège
2023-09-18
Recruiting
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772Glucose Intolerance After a Recent History of Gestational Diabetes
DrugsSemaglutide Injector·Ozempic
Universitaire Ziekenhuizen KU Leuven
Phase 3
252
Aalst, Antwerp, Bruges, Brussels, Ieper, Kortrijk, Leuven, Liège
2023-09-14
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Yvoir, Brussels, Kortrijk, Leuven, Liège
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Ghent, Liège
2023-09-13
Recruiting
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938Community-acquired Pneumonia
Biotest
Phase 3
590
Aalst, Bruges, Brussels, Edegem, Genk, Ghent, Jette, Liège
2023-09-09
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
420
Anderlecht, Liège, Leuven, Antwerp
2023-08-31
Recruiting
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
NCT06183645Chronic Inflammatory Demyelinating Polyneuropathy
Centre Hospitalier Universitaire de Liege
Observational
40
Liège
2023-08-28
Recruiting
Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes
NCT05777330Type1 Diabetes Mellitus
Universitair Ziekenhuis Brussel
Not applicable
75
Liège, Bruges, Antwerp, Ghent, Jette, Leuven
2023-08-09
Active, closed
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740Multiple Sclerosis
DrugsMavenclad·Cladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Observational
366
Brussels, Edegem, Kortrijk, Liège
2023-08-03
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Aalst, Brussels, Edegem, Ghent, Leuven, Liège, Roeselare
2023-08-01
Active, closed
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
NCT06547957Advanced Solid Tumors
iTeos Therapeutics
Phase 1
55
Brussels, Charleroi, Ghent, Liège, Wilrijk
2023-07-07
Rows per page Showing 201–300 of 565
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Belgian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-belgium/city/li-ge?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Belgium and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,062 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 565 of those studies with a site in Liège.

How many clinical trials are recruiting in Liège?

289 of the 565 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 16 have not yet opened recruitment, 247 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.